disufenton sodium has been researched along with clonidine in 1 studies
Studies (disufenton sodium) | Trials (disufenton sodium) | Recent Studies (post-2010) (disufenton sodium) | Studies (clonidine) | Trials (clonidine) | Recent Studies (post-2010) (clonidine) |
---|---|---|---|---|---|
114 | 19 | 15 | 13,692 | 2,044 | 1,394 |
Protein | Taxonomy | disufenton sodium (IC50) | clonidine (IC50) |
---|---|---|---|
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.101 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0353 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0115 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 5.365 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.21 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 5.365 | |
Alpha-2A adrenergic receptor | Bos taurus (cattle) | 0.002 | |
Nischarin | Rattus norvegicus (Norway rat) | 0.3662 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cucchiara, BL; Kasner, SE; Lyden, PD; Messe, SR; Sansing, LH | 1 |
1 trial(s) available for disufenton sodium and clonidine
Article | Year |
---|---|
Anti-adrenergic medications and edema development after intracerebral hemorrhage.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Antioxidants; Benzenesulfonates; Blood Pressure; Brain Edema; Cerebral Hemorrhage; Clonidine; Cohort Studies; Critical Care; Double-Blind Method; Drug Therapy, Combination; Female; Free Radical Scavengers; Glasgow Coma Scale; Humans; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Treatment Outcome | 2011 |